CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

Transparency Market 

Research 

CINV Existing and Pipeline Drugs Market - Global 

Industry Analysis, Size, Share, Growth, Trends and 

Forecast 2014 - 2020 

Published Date 

2014-12-29 

74 Page Report 

Buy Now 

Request Sample 

Press Release 

Chemotherapy Induced Nausea and Vomiting (CINV) Existing and 

Pipeline Drugs Market Expected to Reach USD 1.88 Billion 

Globally in 2020 

Transparency Market Research 

State Tower, 

90, State Street, Suite 700. 

Albany, NY 12207 

United States 

www.transparencymarketresearch.com 

sales@transparencymarketresearch.com

CINV Existing and Pipeline Drugs 

Market 

REPORT DESCRIPTION 

CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, 

Growth, Trends and Forecast 2014 - 2020 

According to a new market report published by Transparency Market Research “CINV Existing and 

Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 

2020,” the global CINV drugs market was valued at USD 1.28 billion in 2013 and is expected to 

grow at a CAGR of 5.7% from 2014 to 2020, to reach an estimated value of USD 1.88 billion in 

2020. 

Chemotherapy induced nausea and vomiting (CINV) refers to nausea and vomiting associated 

with cancer chemotherapy. CINV is one of the most common side effects experienced by cancer 

patients undergoing chemotherapy. Although there are currently several drugs available to 

manage CINV, this side effect continues to be a major concern for patients and oncologists 

associated with chemotherapy. Companies such as Helsinn Holding S.A., Heron Therapeutics, Inc. 

and Tesaro, Inc. are striving to develop new and more efficacious therapeutic solutions to treat 

CINV. 

Browse the full CINV Existing and Pipeline Drugs Market Report at : 

http://www.transparencymarketresearch.com/cinv-market.html 

Aloxi (palonosetron), Zofran (ondansetron), Kytril (granisetron) and Emend (aprepitant) are the 

major available drugs which are used to manage CINV. Recently in October 2014, U.S. FDA 

approved the first fixed combination oral agent, Akynzeo (developed by Helsinn Holding S.A.) for 

the prevention of CINV. Akynzeo, being the first fixed-dose combination providing patients with 

two antiemetics in a single dose, is likely to offer better patient compliance and consequently is 

expected to witness increasing popularity among physicians. 


2



SUSTOL (APF-530) and rolapitant are the two major CINV pipeline drugs that are currently under 

phase III or registration phase and would be introduced in the near future. Approval of these two 

pipeline drugs will be driving the overall CINV drugs market during the forecast period from 2014 

to 2020. In addition to this, continuous increase in number of patients undergoing chemotherapy 

is also expected to play a key role in the growth of CINV drugs market. Various sources indicate 

that approximately 70% to 80% cancer patients on chemotherapy exhibit nausea and vomiting 

as major side effects. 

Get Free Sample Report CINV Existing and Pipeline Drugs Market : 

http://www.transparencymarketresearch.com/sample/sample.php? 

flag=S&rep_id=776 

Two key CINV drugs Aloxi and Emend are going off-patent in 2015, post which a number of 

generic manufacturers are likely to enter in the market with generic versions of these two 

brands. Therefore, patent expiry of Aloxi and Emend has been anticipated to affect market 

revenue during the forecast period, as their generic versions will be sold at 80% to 85% lower 

prices than the branded ones. 

Geographically, North America was the largest regional market for CINV drugs in 2013 with a 

market share of over 45% of the total revenue generated globally, followed by Europe. North 

America it is expected to retain its leading position through 2020, growing at a CAGR of more 

than 7% during the forecast period from 2014 to 2020. On the other hand, the CINV drugs 

market in Asia-Pacific would be primarily driven by the increasing penetration of western 

companies coupled with the growing number of cancer patients. In many countries in Asia-Pacific 

and Rest of the World (RoW) regions, generic manufacturers would be competing with the 

branded CINV drug manufacturers. Owing to the low purchasing power of people, generic 

versions of expired branded drugs are in greater demand in the region. 

Browse the full CINV Existing and Pipeline Drugs Market press release at : 


3



http://www.transparencymarketresearch.com/pressrelease/cinv-market.htm 

GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, 

Inc. are some of the key players actively participating in the CINV drugs market. 

The global CINV existing and pipeline drugs market is segmented as follows: 

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs 

➢ 

Aloxi (palonosetron) 

➢ 

Zofran Generic (ondansetron) 

➢ 

Kytril Generic (granisetron) 

➢ 

Emend (aprepitant) 

➢ 

Akynzeo (netupitant-palonosetron) 

➢ 

SUSTOL (extended release granisetron injection) 

➢ 

Rolapitant 


4



CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography 

➢ 

North America 

➢ 

Europe 

➢ 

Asia-Pacific 

➢ 

Rest of the World (RoW) 

TABLE OF CONTENT 

Chapter 1 Preface 

1.1 Report Description 

1.2 Market Segmentation 

1.3 Research Methodology 

1.3.1 Assumptions 

1.3.2 Sources 

1.3.2.1 Secondary Research 

1.3.2.2 Primary Research 

1.3.3 Models 


5



1.4 List of Abbreviations 

Chapter 2 Executive Summary 

2.1 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020) 

2.2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million) 

2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %) 

Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview 

3.1 Chemotherapy Induced Nausea and Vomiting (CINV) 

3.1.1 Aetiology/Causes for CINV 

3.1.2 Pathogenesis of CINV 

3.1.3 Treatment Recommendations for CINV 

3.1.4 Unmet Needs in the CINV Market 

3.2 Market Dynamics 

3.2.1 Drivers 

3.2.1.1 Growing number of patients undergoing chemotherapy 

3.2.1.2 Anticipated approval of new CINV drugs during the forecast period from 2014 to 2020 

3.2.2 Restraints 

3.2.2.1 Patent expirations of major CINV drugs during the projected period 


6



development 

3.2.2.2 Strict regulatory pathway and high cost associated with the new drug discovery and 

3.2.3 Opportunities 

3.2.3.1 Emphasis on developing breakthrough therapy for the prevention of CINV such as fixeddose 

combination product and other innovative products with enhanced therapeutic efficacy 

3.2.3.2 Focusing on developing nations as they present immense market potential for CINV drugs 

3.3 Event Impact Analysis 

Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD 

Million) 

4.1 Overview 

4.2 CINV Existing Drugs Market 

4.2.1 Global CINV Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million) 

4.2.2 Global CINV Estimated Patient Pool, by Major Drugs, 2012 – 2020 (Thousands) 

%) 

4.2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value 

4.2.4 Aloxi (palonosetron) 

4.2.4.1 Global Aloxi Market Revenue, 2012 – 2020 (USD Million) 

4.2.5 Zofran Generic (ondansetron) 

4.2.5.1 Global Zofran Generic Market Revenue, 2012 – 2020 (USD Million) 

4.2.6 Kytril Generic (granisetron) 


7



4.2.6.1 Global Kytril Generic Market Revenue, 2012 – 2020 (USD Million) 

4.2.7 Emend (aprepitant) 

4.2.7.1 Global Emend Market Revenue, 2012 – 2020 (USD Million) 

4.2.8 Akynzeo (netupitant-palonosetron FDC) 

4.2.8.1 Global Akynzeo Market Revenue, 2015 – 2020 (USD Million) 

4.3 CINV Pipeline Drugs Market 

4.3.1 SUSTOL (granisetron injection extended release) 

4.3.1.1 Global SUSTOL Market Revenue, 2016 – 2020 (USD Million) 

4.3.1.2 SWOT Analysis for SUSTOL 

4.3.1.3 Overview of SUSTOL Phase III study 

4.3.1.3.1 Primary Efficacy Results: Complete Response with Patients Receiving MEC 

4.3.1.3.2 Primary Efficacy Results: Complete Response with Patients Receiving HEC 

4.3.2 Rolapitant 

4.3.2.1 Global Rolapitant Market Revenue, 2015 – 2020 (USD Million) 

4.3.2.2 SWOT Analysis for Rolapitant 

4.3.2.3 Overview of Rolapitant Efficacy Analysis 

Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 – 2020 (USD 

Million) 

5.1 Overview 


8



5.1.1 Global CINV Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million) 

5.1.2 Global CINV Estimated Patient Pool, by Geography, 2012 – 2020 (Thousands) 

5.2 North America 

5.2.1 North America CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 

5.2.2 North America CINV Pipeline Drugs Market Revenue, 2015 – 2020 (USD Million) 

5.2.3 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 – 2020 (Thousands) 

5.3 Europe 

5.3.1 Europe CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 

5.3.2 Europe CINV Pipeline Drugs Market Revenue, 2016 – 2020 (USD Million) 

5.3.3 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 – 2020 (Thousands) 

5.4 Asia-Pacific 

5.4.1 Asia-Pacific CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 

5.5 Rest of the World (RoW) 

5.5.1 RoW CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 

Chapter 6 Competitive Landscape 

6.1 Competitive Landscape 

Chapter 7 Company Profiles 

7.1 GlaxoSmithKline plc 


9



7.1.1 Company Overview 

7.1.2 Financial Overview 

7.1.3 Product Portfolio 

7.1.4 Business Strategies 

7.1.5 Recent Developments 

7.2 Helsinn Holding S.A. 






7.3 Heron Therapeutics, Inc. 






7.4 Merck & Co., Inc. 




10






7.5 Tesaro, Inc. 






List of Figures 

FIG. 1 CINV Existing and Pipeline Drugs: Market Segmentation 

FIG. 2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million) 

FIG. 3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %) 

FIG. 4 Pathogenesis of CINV 

FIG. 5 Unmet Needs in the CINV Market 

FIG. 6 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value %) 

FIG. 7 Global Aloxi Market Revenue, 2012 – 2020 (USD Million) 

FIG. 8 Global Zofran Generic Market Revenue, 2012 – 2020 (USD Million) 

FIG. 9 Global Kytril Generic Market Revenue, 2012 – 2020 (USD Million) 


11



FIG. 10 Global Emend Market Revenue, 2012 – 2020 (USD Million) 

FIG. 11 Global Akynzeo Market Revenue, 2015 – 2020 (USD Million) 

FIG. 12 Global SUSTOL Market Revenue, 2016 – 2020 (USD Million) 

FIG. 13 Primary Efficacy Results: Complete Response with Patients Receiving MEC 

FIG. 14 Primary Efficacy Results: Complete Response with Patients Receiving HEC 

FIG. 15 Global Rolapitant Market Revenue, 2015 – 2020 (USD Million) 

FIG. 16 North America CINV Drugs Market Revenue, 2012 – 2020 (USD Million) 

FIG. 17 Europe CINV Drugs Market Revenue, 2012 – 2020 (USD Million) 

FIG. 18 Asia-Pacific CINV Drugs Market Revenue, 2012 – 2020 (USD Million) 

FIG. 19 RoW CINV Drugs Market Revenue, 2012 – 2020 (USD Million) 

List of Tables 

TABLE 1 List of Abbreviations 

TABLE 2 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020) 

TABLE 3 Chemotherapy Induced Nausea and Vomiting (CINV): Subtypes and Description 

TABLE 4 Treatment Recommendations for CINV 

TABLE 5 Event Impact Analysis: Global CINV Drugs Market 

TABLE 6 Global CINV Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million) 

TABLE 7 Global CINV Estimated Patient Pool, by Major Drugs, 2012 – 2020 (Thousands) 

TABLE 8 SWOT Analysis for SUSTOL 


12



TABLE 9 Efficacy of SUSTOL with Difficult Chemo Regimens 

TABLE 10 SWOT Analysis for Rolapitant 

TABLE 11 Overview of Rolapitant Efficacy Analysis 

TABLE 12 Global CINV Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million) 

TABLE 13 Global CINV Estimated Patient Pool, by Geography, 2012 – 2020 (Thousands) 

TABLE 14 North America CINV Pipeline Drugs Market Revenue, 2015 – 2020 (USD Million) 

TABLE 15 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 – 2020 (Thousands) 

TABLE 16 Europe CINV Pipeline Drugs Market Revenue, 2016 – 2020 (USD Million) 

TABLE 17 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 – 2020 (Thousands) 

TABLE 18 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 19 Helsinn Holding S.A.: Pipeline Product Portfolio 

TABLE 20 Heron Therapeutics, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 21 Heron Therapeutics, Inc.: Pipeline Product Portfolio 

TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 23 Tesaro, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 24 Tesaro, Inc.: Pipeline Product Portfolio 

Browse All Pharmaceutical Market Research Reports @ 

http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html 

About Us 


13



Transparency Market Research is a market intelligence company providing global business information 

reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking 

insight for thousands of decision makers. 

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use 

proprietary data sources and various tools and techniques to gather, and analyze information. Our 

business offerings represent the latest and the most reliable information indispensable for businesses to 

sustain a competitive edge. 

Contact 


90 State Street, 

Suite 700, 

Albany 

NY - 12207 

United States 

Tel: +1-518-618-1030 

USA - Canada Toll Free 866-552-3453 

Email: sales@transparencymarketresearch.com 

Website: http://www.transparencymarketresearch.com/ 

Browse The Market Research Blog : 

http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com 


14

CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?